Triple hormone contraceptive - ANI Pharmaceuticals/Pantarhei Bioscience

Drug Profile

Triple hormone contraceptive - ANI Pharmaceuticals/Pantarhei Bioscience

Alternative Names: Androgen Restored Contraceptive; ARC; Female balance pill - ANI Pharmaceuticals/Pantarhei Bioscience; Pill-Plus; Triple OC

Latest Information Update: 25 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioSante Pharmaceuticals
  • Developer ANI Pharmaceuticals; Pantarhei Bioscience
  • Class Androstenes; Androstenols; Antiandrogens; Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Progesterone congeners; Small molecules
  • Mechanism of Action Dehydroepiandrosterone-replacements; Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Pregnancy
  • No development reported Female sexual dysfunction

Most Recent Events

  • 25 Jul 2018 Triple hormone contraceptive - ANI Pharmaceuticals/Pantarhei Bioscience is available for licensing as of 25 Jul 2018.
  • 20 Oct 2015 Phase-II/III clinical trials in Pregnancy (prevention) in Netherlands (PO)
  • 10 Jun 2015 No recent reports on development identified - Clinical-Phase-Unknown for Pregnancy (prevention) in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top